Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Edwards Lifesciences Corp    EW

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Edwards Lifesciences Corp : Edwards Lifesciences' Chairman and CEO to Exercise Stock Options Under 10b5-1 Stock Trading Plan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/01/2013 | 04:37pm CEST

IRVINE, CA, March 01, 2013 -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that its chairman and chief executive officer, Michael A. Mussallem, has adopted a pre-arranged stock trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934. In May 2013, the plan will begin exercising stock options, the vast majority of which are scheduled to expire in 2014.

The plan anticipates the exercise and sale of 29,500 shares per month at market prices between May 2013 and April 2014. Rule 10b5-1 allows corporate executives to adopt stock trading plans to buy or sell shares of company stock when they are not in possession of material, non-public information. Mussallem plans to enter into similar types of trading plans each year as stock options near their expiration dates in order to spread sales evenly over an extended period of time.

Under the company's stock ownership guidelines, Mussallem is required to own shares of company stock with an aggregate market value equal to six times his base salary. At the conclusion of the plans, Mussallem will still hold shares well in excess of the number required to meet these guidelines. Transactions under these plans will be disclosed publicly through Form 144 and Form 4 filings with the U.S. Securities and Exchange Commission. The Form 4 filings will also be posted on Edwards' investor relations Web site at ir.edwards.com.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at edwards.com.

Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

# # #


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EDWARDS LIFESCIENCES CORP
05/19 EDWARDS LIFESCIENCES CORP (NYSE : EW) Reports Positive Outcome From Self-Expandi..
05/18 EDWARDS LIFESCIENCES' : Every Heartbeat Matters Initiative On Track To Impact 1 ..
05/17 EDWARDS LIFESCIENCES : ' Novel Self-Expanding Transcatheter Heart Valve Demonstr..
05/16 EDWARDS LIFESCIENCES : Real-World Evidence With Edwards SAPIEN 3 Transcatheter V..
05/12 EDWARDS LIFESCIENCES CORPORATION (NY : EW) Files An 8-K Departure of Directors o..
05/12 EDWARDS LIFESCIENCES CORP : Change in Directors or Principal Officers, Submissio..
05/11 EDWARDS LIFESCIENCES : Patent Issued for Systems and Methods for Placing a Coapt..
05/04 EDWARDS LIFESCIENCES : Trademark Application for "ENDORETURN" Filed by Edwards L..
05/04 EDWARDS LIFESCIENCES : Trademark Application for "TRUWAVE" Filed by Edwards Life..
05/04 EDWARDS LIFESCIENCES : To Webcast Annual Meeting Of Stockholders
More news
Sector news : Advanced Medical Equipment & Technology - NEC
05/23DJFirms Persuade SEC on Profit Metric -- WSJ
05/22DJCompanies Are Winning the Battle Over Adjusted Earnings
05/17 PHILIPS CEO : uptake of connected care products progressing slowly
05/15DJMARKET SNAPSHOT : Stock Market Sets Fresh Records As Oil Rallies
05/15 Thermo Fisher to buy Patheon for $5.2 billion to expand biopharma services
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
05/26 BofA/Merrill Lynch bullish on Edwards Lifesciences; sees 22% upside
05/16 Lotus Blooms In Phase III
05/16 Edwards' SAPIEN 3 valve shows significant treatment benefit in large post-mar..
05/16 Premarket analyst action - healthcare
05/08 VALUATION DASHBOARD : Healthcare - Update
Advertisement
Financials ($)
Sales 2017 3 349 M
EBIT 2017 1 006 M
Net income 2017 777 M
Finance 2017 472 M
Yield 2017 -
P/E ratio 2017 31,86
P/E ratio 2018 28,89
EV / Sales 2017 7,02x
EV / Sales 2018 6,32x
Capitalization 23 970 M
More Financials
Chart EDWARDS LIFESCIENCES CORP
Duration : Period :
Edwards Lifesciences Corp Technical Analysis Chart | EW | US28176E1082 | 4-Traders
Full-screen chart
Technical analysis trends EDWARDS LIFESCIEN...
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 122 $
Spread / Average Target 6,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Stanton J. Rowe Chief Scientific Officer & VP-Advanced Technology
John T. Cardis Independent Director
William J. Link Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
EDWARDS LIFESCIENCES C..21.93%23 970
THERMO FISHER SCIENTIF..22.54%67 845
DANAHER CORPORATION8.43%58 584
BOSTON SCIENTIFIC CORP..26.31%37 412
INTUITIVE SURGICAL, IN..43.55%33 538
PHILIPS8.28%32 627
More Results